53 results on '"Darsow U"'
Search Results
2. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.
- Author
-
Darsow, U., Sbornik, M., Rombold, S., Katzer, K., Sonnenburg, F., Behrendt, H., and Ring, J.
- Subjects
- *
SMALLPOX vaccines , *ECZEMA , *ALLERGIC rhinitis , *VACCINATION complications , *IMMUNODEFICIENCY - Abstract
Background Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara ( MVA)- BN, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile. Methods A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects. Healthy subjects, subjects with a history of AE, subjects with mild active AE and subjects with mild allergic rhinitis without AE were equally allocated into four groups. MVA- BN was injected s.c. in a dose of 108 TCID50 twice in a 4-week interval. Results No serious or unexpected adverse reactions were reported. All subjects experienced mild to moderate pain and redness at the injection site. Dermatologic examinations did not reveal any unfavourable reactions to the study medication, particularly no sign or exacerbation of eczema for as long as 196 days. All subjects seroconverted after two vaccinations and no significant difference in antibody titres between the four different groups was observed. Conclusions A good safety profile of the MVA- BN vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with AE or other atopic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Heterogeneity of molecular sensitization profiles in grass pollen allergy - implications for immunotherapy?
- Author
-
Darsow, U., Brockow, K., Pfab, F., Jakob, T., Petersson, C. J., Borres, M. P., Ring, J., Behrendt, H., and Huss‐Marp, J.
- Subjects
- *
ALLERGIES , *IMMUNOTHERAPY , *HEALTH outcome assessment , *PROVOCATION tests (Medicine) , *IMMUNOGLOBULIN E - Abstract
Background Data on molecular allergy diagnostics in adults with grass pollen allergy with regard to conjunctival and nasal provocation test outcome and specific immunotherapy are lacking to date. Objective To assess whether molecular allergy diagnostics for grass pollen allergens could help with predicting provocation test outcomes and serve as a basis for future component-resolved specific immunotherapy. Methods Sera of 101 adults with grass pollen allergy was analysed for IgE against timothy grass pollen ( Phleum pratense), rPhl p 1, rPhl p 2, nPhl p 4, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 11 and rPhl p12 and correlated with the individuals' outcome in the nasal and conjunctival provocation tests and investigated in regard to a potential component-resolved specific immunotherapy. Results An increasing number of sensitizations to timothy grass allergens was correlated to a positive reaction in the conjunctival (4.9 vs. 3.6, P = 0.003) and nasal provocation tests (4.5 vs. 2.2, P = 0.0175). In molecular sensitization profiles, a substantial heterogeneity was detected, with none of the patients exactly matching the allergen composition of a previously published component-resolved specific immunotherapy containing Phl p 1, Phl p 2, Phl p 5a/b and Phl p 6. The results indicate that in 95% of the patients, a proportion of 50% of timothy-IgE would be targeted with such a specific immunotherapy, while in 50% and 10% of patients, 80% and 90% of timothy-IgE would be targeted, respectively. Conclusion and Clinical Relevance Molecular allergy diagnostics is a prerequisite for future component-resolved specific immunotherapy due to the high heterogeneity of sensitization profiles. However, of current clinical relevance is the observed correlation between the number of sensitizations and provocation test outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Can Immunoglobulin E-measurement replace challenge tests in allergic rhinoconjunctivits to grass pollen?
- Author
-
Huss-Marp, J., Darsow, U., Brockow, K., Pfab, F., Weichenmeier, I., Schober, W., Petersson, C. J., Borres, M. P., Ring, J., and Behrendt, H.
- Subjects
- *
IMMUNOGLOBULIN E , *DOSE-response relationship in biochemistry , *ALLERGY diagnosis , *BRONCHIAL spasm , *POLLEN - Abstract
Summary [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis.
- Author
-
Darsow, U., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A., Gelmetti, C., Svensson, A., Deleuran, M., Calza, A.-M., Giusti, F., Lübbe, J., Seidenari, S., and Ring, J.
- Subjects
- *
ATOPIC dermatitis treatment , *ANTI-inflammatory agents , *ANTIHISTAMINES , *ULTRAVIOLET radiation , *ECZEMA - Abstract
Background The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria. Management of AD must consider the symptomatic variability of the disease. Methods EADV eczema task force developed its guideline for atopic dermatitis diagnosis and treatment based on literature review and repeated consenting group discussions. Results and Discussion Basic therapy relies on hydrating topical treatment and avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment based on topical glucocorticosteroids and topical calcineurin antagonists is used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, but the topical calcineurin inhibitors, tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) can relieve pruritus, but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength or UVB 311 nm. Dietary recommendations should be specific and given only in diagnosed individual food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Stress-induced exacerbations may make psychosomatic counselling recommendable. ‘Eczema school’ educational programmes have been proven to be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
6. EAACI/GA2LEN Position paper: Present status of the atopy patch test.
- Author
-
Turjanmaa, K., Darsow, U., Niggemann, B., Ranc, F., Vanto, T., and Werfel, T.
- Subjects
- *
ALLERGENS , *ATOPIC dermatitis , *ECZEMA , *FOOD , *TECHNICAL reports - Abstract
A number of scientific reports have been published on patch tests with protein allergens performed on patients with atopic eczema (AE). Evaluation of eczematous skin lesions with an atopy patch test (APT) can be used as a diagnostic tool in characterizing patients with aeroallergen- and food-triggered AE. Indications for testing with APT, choice of allergens (aeroallergens and foods), test materials and technique, including present knowledge on sensitivity and specificity, are reviewed on the basis of available literature. This position paper also points out the need for future research on the clinical use of the APT. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
7. No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients.
- Author
-
Oldhoff, J. M., Darsow, U., Werfel, T., Bihari, I. C., Katzer, K., Laifaoui, J., Plötz, S., Kapp, A., Knol, E. F., Bruijnzeel-Koomen, C. A. F. M., Ring, J., and de Bruin-Weller, M. S.
- Subjects
- *
INTERLEUKINS , *ATOPIC dermatitis , *ECZEMA , *EOSINOPHILS , *CHEMOKINES , *GENETICS , *THERAPEUTICS - Abstract
Background: The atopy patch test (APT) is an in vivo model to study the induction of eczema by inhalant allergens in atopic dermatitis (AD) patients. Mepolizumab is a monoclonal antibody to interleukin-5, which reduces peripheral blood eosinophils. Previously, we reported that mepolizumab treatment did not result in clinical improvement in AD. The current study investigates the effect of mepolizumab therapy on the APT in the same patients. Methods: Mepolizumab treatment was given at days 0 and 7 in a double-blind placebo-controlled design. The APT was applied at days –2, 0, 14 and 28. Clinical evaluation of each APT was conducted 48 h after application at days 0, 2, 16 and 30. Skin biopsies were taken at days 0, 2 and 16 for eosinophil counts. Results: The mepolizumab-treated group showed no significant reduction in macroscopic outcome of the APT. Tissue eosinophils were reduced in the mepolizumab-treated group at day 16 compared with placebo; however, this was not significant. Conclusion: Mepolizumab therapy cannot prevent the eczematous reaction induced by the APT. Furthermore, the influx of tissue eosinophil numbers in the APT is not significantly inhibited after mepolizumab treatment compared with placebo, despite a significant reduction in peripheral blood eosinophils. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. Atopic eczema: what's new?
- Author
-
Möhrenschlager, M., Darsow, U., Schnopp, C., and Ring, J.
- Subjects
- *
ECZEMA , *SKIN inflammation , *SKIN diseases , *ITCHING , *ALLERGENS - Abstract
Atopic eczema (AE) is a chronic inflammatory skin disease characterized by recurrent intense pruritus and a typical age-related distribution of skin lesions. Several new aspects with regard to the pathogenetic background as well as strategies for prevention, diagnosis and treatment of AE have emerged. There are ongoing studies on genetic susceptibility loci, as well as environmental and nutritional factors associated with an increase or a decrease of AE lesions. The atopy patch test is now available for identification of allergens in aeroallergen-triggered AE. New topical therapies, such as the calcineurin inhibitors, have broadened the therapeutic armamentarium substantially. In order to increase knowledge and coping strategies, patient education programs have been launched. Learning objective Upon completing this paper, the reader should be aware of new developments in AE, especially on nomenclature, prevention strategies, diagnostic tests, as well as therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. Position paper on diagnosis and treatment of atopic dermatitis.
- Author
-
Darsow, U., Lübbe, J., Taïeb, A., Seidenari, S., Wollenberg, A., Calza, A.M., Giusti, F., and Ring, J.
- Subjects
- *
ATOPIC dermatitis , *ALLERGIES , *SKIN inflammation , *ANTI-infective agents , *IMMUNOLOGICAL adjuvants , *FOOD allergy - Abstract
The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria. Management of AD must consider the symptomatic variability of the disease. It is based on hydrating topical treatment, and avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment is used for exacerbation management. Topical corticosteroids remain the first choice. Systemic anti-inflammatory treatment should be kept to a minimum, but may be necessary in rare refractory cases. The new topical calcineurin inhibitors (tacrolimus and pimecrolimus) expand the available choices of topical anti-inflammatory treatment. Microbial colonization and superinfection (e.g. withStaphylococcus aureus,Malassezia furfur) can have a role in disease exacerbation and can justify the use of antimicrobials in addition to the anti-inflammatory treatment. Evidence for the efficacy of systemic antihistamines in relieving pruritus is still insufficient, but some patients seem to benefit. Adjuvant therapy includes ultraviolet (UV) irradiation preferably of UVA wavelength; UVB 311 nm has also been used successfully. Dietary recommendations should be specific and only given in diagnosed individual food allergy. Stress-induced exacerbations may make psychosomatic counselling recommendable.‘Eczema school’ educational programmes have proved to be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
10. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis.
- Author
-
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., Bruijnzeel-Koomen, C. A. F. M., Ring, J., and de Bruin-Weller, M. S.
- Subjects
- *
PLACEBOS , *GRANULOCYTES , *SKIN inflammation , *INTERLEUKINS , *LYMPHOKINES , *ATOPIC dermatitis - Abstract
Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD.Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of‘success’ to treatment was defined as the percentage of patients with at least‘marked improvement’ after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticason propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded.Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05).Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
11. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study.
- Author
-
Darsow, U., Laifaoui, J., Kerschenlohr, K., Wollenberg, A., Przybilla, B., Wüthrich, B., Borelli Jr., S., Giusti, F., Seidenari, S., Drzimalla, K., Simon, D., Disch, R., Borelli, S., Devillers, A. C. A., Oranje, A. P., de Raeve, L., Hachem, J.-P., Dangoisse, C., Blondeel, A., and Song, M.
- Subjects
- *
ALLERGENS , *ECZEMA , *IMMUNOGLOBULIN E , *POLLEN , *PETROLATUM , *SKIN inflammation - Abstract
The atopy patch test (APT) was proposed to evaluate IgE-mediated sensitizations in patients with atopic eczema (AE).The prevalence and agreement with clinical history and specific IgE (sIgE) of positive APT reactions was investigated in six European countries using a standardized method.A total of 314 patients with AE in remission were tested in 12 study centers on clinically uninvolved, non-abraded back skin with 200 index of reactivity (IR)/g of house dust miteDermatophagoides pteronyssinus, cat dander, grass, and birch pollen allergen extracts with defined major allergen contents in petrolatum. Extracts of egg white, celery and wheat flour with defined protein content were also patch tested. APT values were evaluated at 24, 48, and 72 h according to the European Task Force on Atopic Dermatitis (ETFAD) guidelines. In addition, skin-prick test (SPT) and sIgE and a detailed history on allergen-induced eczema flares were obtained.Previous eczema flares, after contact with specific allergens, were reported in 1% (celery) to 34% (D. pteronyssinus) of patients. The frequency of clear-cut positive APT reactions ranged from 39% withD. pteronyssinusto 9% with celery. All ETFAD intensities occured after 48 and 72 h. Positive SPT (16–57%) and elevated sIgE (19–59%) results were more frequent. Clear-cut positive APT with all SPT and sIgE testing negative was seen in 7% of the patients, whereas a positive APT without SPT or sIgE for the respective allergen was seen in 17% of the patients. APT, SPT and sIgE results showed significant agreement with history for grass pollen and egg white (two-sided Pr > |Z| ≤ 0.01). In addition, SPT and sIgE showed significant agreement with history for the other aeroallergens. With regard to clinical history, the APT had a higher specificity (64–91% depending on the allergen) than SPT (50–85%) or sIgE (52–85%). Positive APT were associated with longer duration of eczema flares and showed regional differences. In 10 non-atopic controls, no positive APT reaction was seen.Aeroallergens and food allergens are able to elicit eczematous skin reactions after epicutaneous application. As no gold standard for aeroallergen provocation in AE exists, the relevance of aeroallergens for AE flares may be evaluated by APT in addition to SPT and sIgE. The data may contribute to the international standardization of the APT. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
12. Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests.
- Author
-
Darsow, U. and Ring, J.
- Subjects
- *
ATOPIC dermatitis , *ECZEMA , *ALLERGENS , *DIAGNOSIS - Abstract
Aeroallergens and food allergens are relevant eliciting factors of atopic eczema. This article focuses on the methods used for diagnosis in patients with suspected allergy to airborne or dietary allergens and who are suffering from atopic eczema. In addition to classical tests of IgE-mediated hypersensitivity (intracutaneous or in vitro testing), the role of provocation procedures is described. For aeroallergens, the atopy patch test yields the most specific results with regard to clinical history as compared with classical methods. For food allergens and pseudoallergic reactions to additives, this holds true for the double-blind, placebo-controlled food challenge. The methods and their limitations are discussed from a practical point of view. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
13. Variable response to low‐dose naltrexone in patients with Darier disease: a case series.
- Author
-
Boehmer, D., Eyerich, K., Darsow, U., Biedermann, T., and Zink, A.
- Subjects
- *
ITCHING , *NALTREXONE , *GENETIC code , *COST functions , *DISEASES - Abstract
Background: Darier disease is a rare autosomal‐dominant genodermatosis with a loss of function of a Ca2+‐ATPase pump (SERCA2‐pump). Clinically, the disease is characterized by red–brown keratotic papules mainly in seborrhoeic areas and has only limited and unsatisfactory treatment options. Previously, low‐dose naltrexone was described as a successful treatment option in Hailey–Hailey disease, a genodermatosis with a genetic mutation coding for a similar loss of function of a Ca2+‐ATPase pump (hSPCA1‐pump). Objective: To assess the efficacy of low‐dose naltrexone as a treatment option in Darier disease. Methods: Six patients with biopsy‐proven Darier disease (four had severe, one had moderate and one mild clinical manifestations). The patients received off‐label therapy with naltrexone [5 mg per os (p.o.)] and magnesium [200 mg p.o.]. Patients were followed up every 4 weeks for minimally 12 weeks. Upon clinical presentation, the disease severity and subjective pain and itch scores were assessed, and standardized photographs were obtained. Results: The clinical response to naltrexone varied after 12 weeks. The four patients with severe Darier disease showed worsening after initial improvement during the first 4 weeks, whereas the two patients with a mild to moderate clinical manifestation clearly improved, showing almost full remission after 12 weeks with complete flattening of the keratotic papules. Conclusion: Low‐dose naltrexone did not have an effect on severe Darier disease compared to Hailey–Hailey disease, but it was beneficial in mild to moderate forms of the disease. Further studies are needed to confirm these observations of variable responses. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Increasing the COVID‐19 immunization rate through allergy testing.
- Author
-
Bent, R. K., Weinbrenner, J., Faihs, V., Steffens, S., Nau, T., Vitus, M., Mathes, S., Darsow, U., Biedermann, T., and Brockow, K.
- Subjects
- *
COVID-19 pandemic , *IMMUNIZATION , *ALLERGIES , *LIKERT scale , *COVID-19 vaccines , *ITCHING - Abstract
Background: Vaccination of the population is required to combat the COVID‐19 pandemic. Allergy testing could reduce anxiety towards COVID‐19 vaccination and thereby may increase vaccination rate, however, its effectiveness remains unclear. Methods: One hundred and thirty prospective real‐life patients in need of but not daring to get vaccinated asked for allergy workup for COVID‐19 vaccine hypersensitivity in 2021/2022. Characterization of patients, identification of anxieties, decrease of patient's anxiety levels, overall vaccination rate and adverse reactions after vaccination were assessed. Results: Tested patients were characterized by being female (91.5%) and having a high rate of previous allergies (e.g. to food 55.4%, drugs 54.6%, or previous vaccinations 50%) and dermatological disease (29.2%) but not always had medical contraindications for COVID‐19 vaccination. Sixty one patients (49.6%) were highly concerned (4‐6, Likert scale 0‐6) about vaccination and 47 (37.6%) expressed resolving thoughts about vaccinaion anaphylaxis (3‐6, Likert scale 0‐6). However only 35 patients (28.5%) were scared of getting COVID‐19 within 2 months (4–6, Likert scale 0–6) and only 11 (9%) patients had high expectations of getting COVID‐19 (4–6, Likert scale 0–6). Allergy testing significantly (p < 0.01 to p < 0.05 respectively) reduced the median anxiety of allergic symptoms following vaccination: dyspnoea (4.2–3.1), to faint (3.7–2.7), long‐term consequences (3.6–2.2), pruritus (3.4–2.6), skin rash (3.3–2.6) and death (3.2–2.6). After allergy testing, most patients (108/122, 88.5%) let themselves be vaccinated within 60 days. Revaccinated patients with previous symptoms experienced a reduction of symptoms (p < 0.05) upon revaccination. Conclusions: Patients not daring to get vaccinated have more anxiety towards vaccination than to acquire COVID‐19. For those, allergy testing excludes vaccine allergy, and is a tool to increase vaccination willingness and thereby helps to combat vaccination hesitancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Added sensitivity of component-resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis.
- Author
-
Michel, J., Brockow, K., Darsow, U., Ring, J., Schmidt‐Weber, C. B., Grunwald, T., Blank, S., and Ollert, M.
- Subjects
- *
ALLERGIES , *HYMENOPTERA , *VENOM , *SENSITIVITY analysis , *TRYPTASE , *MAST cell disease , *PATIENTS - Abstract
Background Anaphylaxis caused by hymenoptera venom allergy is associated with elevation of baseline serum tryptase ( sBT) and/or mastocytosis in about 5% of patients. Up to now, no information has become available on single venom allergen sIgE reactivity and the usefulness of component-resolved approaches to diagnose this high-risk patient group. To address the component-resolved sIgE sensitization pattern and diagnostic sensitivity in hymenoptera venom-allergic patients with elevated sBT levels and/or mastocytosis, a panel of yellow jacket and honeybee venom allergens was applied on a widely used IgE immunoassay platform. Methods Fifty-three patients with mastocytosis and/or elevated sBT tryptase level and systemic reactions to hymenoptera venoms were analyzed for their IgE reactivity to recombinant yellow jacket and honeybee venom allergens by Immulite3 g. Results sIgE reactivity to Ves v 1, Ves v 5, Api m 1 to Api m 4 and Api m 10 was found at a similar frequency in hymenoptera venom-allergic patients with and without elevated sBT levels and/or mastocytosis. However, the use of the recombinant allergens and a diagnostic cutoff of 0.1 kUA/L allowed the diagnosis of patients with otherwise undetectable IgE to venom extract. The diagnostic sensitivity of yellow jacket venom allergy using the combination of Ves v 1 and Ves v 5 was 100%. Conclusions In high-risk patients with elevated sBT levels and/or mastocytosis, the use of molecular components and decreasing the threshold sIgE level to 0.1 kUA/L may be needed to avoid otherwise undetectable IgE to hymenoptera venom extracts in about 8% of such patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. A new basophil activation test using CD63 and CCR3 in allergy to antibiotics.
- Author
-
Eberlein, B., Suárez, I. León, Darsow, U., Ruëff, F., Behrendt, H., and Ring, J.
- Subjects
- *
BASOPHILS , *ALLERGIES , *ANTIBIOTICS , *ANTI-infective agents , *IMMUNOGLOBULIN E - Abstract
Background Flow cytometric basophil activation tests (BAT) have been developed as cellular tests for in vitro diagnosis of IgE-mediated reactions. Different markers and techniques have been used after stimulation with various allergens. Objective It was the aim of the present study to compare an established BAT (Flow-CAST®) with a newly developed basophil activation protocol using CD63 and CCR3 (Flow2 CAST®) in patients with type-I allergy to antibiotics. Materials and methods Twenty-four patients with a history of type-I allergy to antibiotics were examined. A careful allergy history was taken, and skin tests and determination of specific IgE antibodies were performed. Two different BAT using CD63 expression but different protocols were carried out after stimulation with different concentrations of antibiotics. Fifteen healthy subjects without a history of antibiotic allergy were studied as controls. Results The Flow2 CAST® showed a higher sensitivity than the Flow-CAST® (55% vs. 53%) with regard to patients' history. Specificity was 80% both for the Flow2 CAST® and for the Flow-CAST® with regard to controls with negative history and negative RAST. Conclusion These results show the value of two different BAT as cellular tests in the in vitro diagnosis of patients with antibiotic allergy with equal specificity and a slightly higher sensitivity for the Flow2 CAST®. Cite this as: B. Eberlein, I. León Suárez, U. Darsow, F. Ruëff, H. Behrendt and J. Ring, Clinical & Experimental Allergy, 2010 (40) 411–418. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
- Author
-
Plötz S, Simon H, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, and Ring J
- Published
- 2003
18. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts.
- Author
-
Ring, J., Worm, M., Wollenberg, A., Thyssen, J.P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T., Bruin‐Weller, M.S., Chernyshov, P.V., Christen‐Zaech, S., Cork, M., Darsow, U., Flohr, C., Fölster‐Holst, R., Gelmetti, C., Gieler, U., Gutermuth, J., and Heratizadeh, A.
- Subjects
- *
COVID-19 vaccines , *SKIN diseases , *ALLERGIES , *MEDICAL personnel , *ECZEMA , *PHYSICIANS - Abstract
Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non-financial support from LEO Pharma, Pierre Fabre, Sanofi-Genzyme and Bioderma. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
19. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics.
- Author
-
Thyssen, J.P., Vestergaard, C., Barbarot, S., Bruin‐Weller, M.S., Bieber, T., Taieb, A., Seneschal, J., Cork, M.J., Paul, C., Flohr, C., Weidinger, S., Trzeciak, M., Werfel, T., Heratizadeh, A., Darsow, U., Simon, D., Torrelo, A., Chernyshov, P.V., Stalder, J.‐F., and Gelmetti, C.
- Subjects
- *
ADULTS , *ATOPIC dermatitis , *COVID-19 , *SARS-CoV-2 , *TASK forces - Abstract
Dr. Chernyshov, Dr. Stalder, Dr. Svensson, Dr. Kunz reports no conflict of interest. At least 3 weeks are recommended between the two COVID-19 vaccine doses, which increases the risk of AD flares and loss of AD control if the systemic AD medication is paused or reduced in dose for longer periods. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
20. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.
- Author
-
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J.P., Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M.J., Kunz, B., Fölster‐Holst, R., Trzeciak, M., Darsow, U., Szalai, Z., Deleuran, M., Kobyletzki, L., Barbarot, S., Heratizadeh, A., and Gieler, U.
- Subjects
- *
ATOPIC dermatitis , *ECZEMA , *TASK forces , *COAL tar , *DISEASE exacerbation , *ANTI-inflammatory agents - Abstract
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrier‐stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti‐inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid‐potency corticosteroids are proven agents for proactive therapy, which is defined as the long‐term intermittent anti‐inflammatory therapy of frequently relapsing skin areas. Systemic anti‐inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit–risk ratio. The IL‐4R‐blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side‐effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R‐blockers) only have limited effects on AD‐related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient‐specific, and elimination diets should only be advised in case of proven food allergy. Allergen‐specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress‐induced exacerbations. Efficacy‐proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis.
- Author
-
Thyssen, J.P., Vestergaard, C., Deleuran, M., Bruin‐Weller, M.S., Bieber, T., Taieb, A., Seneschal, J., Cork, M.J., Paul, C., Flohr, C., Weidinger, S., Trzeciak, M., Werfel, T., Heratizadeh, A., Barbarot, S., Darsow, U., Simon, D., Torrelo, A., Chernyshov, P.V., and Stalder, J.‐F.
- Subjects
- *
ATOPIC dermatitis , *TASK forces , *MEDICAL personnel , *CHILD patients , *ECZEMA , *TREATMENT effectiveness , *NASAL polyps - Abstract
Editor Atopic dermatitis (AD), a common inflammatory skin condition characterized by chronic or relapsing episodes of eczema, itch and sleep disturbance,1 is associated with psychiatric, infectious and allergic comorbidities. Dr. Hijnen has been investigator, speaker or consultant for Abbvie, Eli Lilly, Incyte, LeoPharma, MedImmune/Astrazeneca, Pfizer, Sanofi and ThermoFisher. Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi-Genzyme, Pfizer, Bencard, LEO Pharma and Mylan. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
22. Plantar Erythrodysesthesia Caused by Antiretroviral Treatment: A Case Report and Review of the Literature.
- Author
-
Aigner, B., Brockow, K., Darsow, U., Ring, J., and Plötz, S. G.
- Subjects
- *
ANTIVIRAL agents , *HIV-positive persons , *CUTANEOUS manifestations of general diseases , *CANCER chemotherapy , *MEDICINE in literature - Abstract
Palmoplantar erythrodysesthesia is an uncommon localised cutaneous reaction to certain chemotherapeutic agents and characterized by painful palmoplantar erythema and dysesthesia. To the best of our knowledge, we report the first case of plantar erythrodysesthesia in a 40-year-old male patient receiving an antiretroviral combination therapy for HIV [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients.
- Author
-
Seegräber, M., Worm, M., Werfel, T., Svensson, A., Novak, N., Simon, D., Darsow, U., Augustin, M., and Wollenberg, A.
- Subjects
- *
ATOPIC dermatitis , *HERPES simplex virus , *ECZEMA , *DISEASE risk factors , *VIRUS diseases - Abstract
Background: Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin disease with the herpes simplex virus. Knowledge on clinical characteristics, risk factors and recurrent disease is limited. Our aim was to better define clinical characteristics and risk factors for EH and especially for recurrent EH. Methods: A retrospective analysis of EH cases assessed the history, clinical signs, prior treatment and laboratory results using a predefined questionnaire. Results: A total of 224 EH cases from eight European centres were included. Extrinsic AD was identified as risk factor for EH, and only one patient suffered from intrinsic AD. Early onset of AD was identified as risk factor for recurrent EH. Pretreatment with topical steroids, systemic steroids, topical calcineurin inhibitors or plain emollients reflected standard therapy. Many patients showed AD lesions without EH, but skin without AD lesions was never affected by herpetic lesions. Conclusion: Patients with clinically active, extrinsic AD are at risk of EH. Recurrent EH is associated with confounders of severe atopic distortion and requires active AD lesions for clinical manifestation. Recurrent eczema herpeticum mainly affects patients with early onset of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period.
- Author
-
Vestergaard, C., Wollenberg, A., Barbarot, S., Christen‐Zaech, S., Deleuran, M., Spuls, P., Flohr, C., Trzeciak, M., von Kobyletzki, L., Seneschal, J., Paul, C., Bieber, T., Werfel, T., Fölster‐Holst, R., Darsow, U., Gieler, U., Svensson, Å., Cork, M., Stalder, J.‐F., and De Raeve, L.
- Subjects
- *
ATOPIC dermatitis , *GRAFT versus host disease , *TASK forces , *SCIENTIFIC literature , *POTASSIUM permanganate - Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up‐to‐date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Non‐invasive imaging in dermatology and the unique potential of raster‐scan optoacoustic mesoscopy.
- Author
-
Hindelang, B., Aguirre, J., Schwarz, M., Berezhnoi, A., Eyerich, K., Ntziachristos, V., Biedermann, T., and Darsow, U.
- Subjects
- *
DERMATOLOGY , *LIGHT absorption , *SKIN diseases , *IMAGE - Abstract
In recent years, several non‐invasive imaging methods have been introduced to facilitate diagnostics and therapy monitoring in dermatology. The microscopic imaging methods are restricted in their penetration depth, while the mesoscopic methods probe deeper but provide only morphological, not functional, information. 'Raster‐scan optoacoustic mesoscopy' (RSOM), an emerging new imaging technique, combines deep penetration with contrast based on light absorption, which provides morphological, molecular and functional information. Here, we compare the capabilities and limitations of currently available dermatological imaging methods and highlight the principles and unique abilities of RSOM. We illustrate the clinical potential of RSOM, in particular for non‐invasive diagnosis and monitoring of inflammatory and oncological skin diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Quantification of skin sensitivity to ultraviolet radiation using ultrawideband optoacoustic mesoscopy.
- Author
-
Hindelang, B., Aguirre, J., Berezhnoi, A., Biedermann, T., Darsow, U., Eberlein, B., and Ntziachristos, V.
- Subjects
- *
ULTRAVIOLET radiation , *SKIN - Abstract
Dear Editor, Phototesting is used to assess individual sensitivity to ultraviolet (UV) radiation in order to determine adequate UV dosage for phototherapy.1 Under the standard procedure, small skin areas are exposed to increasing doses of UV radiation. Moreover, the results indicate that UWB-RSOM could be a useful tool to detect the suberythemal response of the skin to UV radiation, which may increase the sensitivity of phototesting. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
27. Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper.
- Author
-
Pfaar, O., Bastl, K., Berger, U., Buters, J., Calderon, M. A., Clot, B., Darsow, U., Demoly, P., Durham, S. R., Galán, C., Gehrig, R., Gerth van Wijk, R., Jacobsen, L., Klimek, L., Sofiev, M., Thibaudon, M., and Bergmann, K. C.
- Subjects
- *
RHINITIS , *POLLEN , *IMMUNOTHERAPY , *TREATMENT effectiveness , *RANDOMIZED controlled trials - Abstract
Background Clinical efficacy of pollen allergen immunotherapy (AIT) has been broadly documented in randomized controlled trials. The underlying clinical endpoints are analysed in seasonal time periods predefined based on the background pollen concentration. However, any validated or generally accepted definition from academia or regulatory authorities for this relevant pollen exposure intensity or period of time (season) is currently not available. Therefore, this Task Force initiative of the European Academy of Allergy and Clinical Immunology ( EAACI) aimed to propose definitions based on expert consensus. Methods A Task Force of the Immunotherapy and Aerobiology and Pollution Interest Groups of the EAACI reviewed the literature on pollen exposure in the context of defining relevant time intervals for evaluation of efficacy in AIT trials. Underlying principles in measuring pollen exposure and associated methodological problems and limitations were considered to achieve a consensus. Results The Task Force achieved a comprehensive position in defining pollen exposure times for different pollen types. Definitions are presented for 'pollen season', 'high pollen season' (or 'peak pollen period') and 'high pollen days'. Conclusion This EAACI position paper provides definitions of pollen exposures for different pollen types for use in AIT trials. Their validity as standards remains to be tested in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Application of recombinant antigen 5 allergens from seven allergy-relevant Hymenoptera species in diagnostics.
- Author
-
Schiener, M., Eberlein, B., Moreno‐Aguilar, C., Pietsch, G., Serrano, P., McIntyre, M., Schwarze, L., Russkamp, D., Biedermann, T., Spillner, E., Darsow, U., Ollert, M., Schmidt‐Weber, C. B., and Blank, S.
- Subjects
- *
HYMENOPTERA , *BITES & stings , *ANAPHYLAXIS , *ALLERGIES , *VENOM , *PAPER wasps , *FIRE ants - Abstract
Background Hymenoptera stings can cause severe anaphylaxis in untreated venom-allergic patients. A correct diagnosis regarding the relevant species for immunotherapy is often hampered by clinically irrelevant cross-reactivity. In vespid venom allergy, cross-reactivity between venoms of different species can be a diagnostic challenge. To address immunological IgE cross-reactivity on molecular level, seven recombinant antigens 5 of the most important Vespoidea groups were assessed by different diagnostic setups. Methods The antigens 5 of yellow jackets, hornets, European and American paper wasps, fire ants, white-faced hornets, and Polybia wasps were recombinantly produced in insect cells, immunologically and structurally characterized, and their sIgE reactivity assessed by Immuno CAP, ELISA, cross-inhibition, and basophil activation test ( BAT) in patients with yellow jacket or Polistes venom allergy of two European geographical areas. Results All recombinant allergens were correctly folded and structural models and patient reactivity profiles suggested the presence of conserved and unique B-cell epitopes. All antigens 5 showed extensive cross-reactivity in sIgE analyses, inhibition assays, and BAT. This cross-reactivity was more pronounced in Immuno CAP measurements with venom extracts than in sIgE analyses with recombinant antigens 5. Dose-response curves with the allergens in BAT allowed a differentiated individual dissection of relevant sensitization. Conclusions Due to extensive cross-reactivity in various diagnostic settings, antigens 5 are inappropriate markers for differential sIgE diagnostics in vespid venom allergy. However, the newly available antigens 5 from further vespid species and the combination of recombinant allergen-based sIgE measurements with BAT represents a practicable way to diagnose clinically relevant sensitization in vespid venom allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.
- Author
-
Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., Kobyletzki, L., Taieb, A., Bruin ‐ Weller, M., Werfel, T., Trzeciak, M., Vestergard, C., Ring, J., Darsow, U., Bieber, T., Chernychov, P., Christen ‐ Zäch, S., and De Raeve, L
- Subjects
- *
ATOPIC dermatitis , *SKIN inflammation , *HYDRATION , *TACROLIMUS , *IMMUNOSUPPRESSION , *IMMUNE response - Abstract
Atopic dermatitis ( AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using evaluated clinical criteria. Disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as SCORAD. The management of AD must consider the clinical and pathogenic variabilities of the disease and also target flare prevention. Basic therapy includes hydrating topical treatment, as well as avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment of visible skin lesions is based on topical glucocorticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Topical calcineurin inhibitors are preferred in sensitive locations. Tacrolimus and mid-potent steroids are proven for proactive therapy, which is long-term intermittent anti-inflammatory therapy of the frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is indicated for severe refractory cases. Biologicals targeting key mechanisms of the atopic immune response are promising emerging treatment options. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) may diminish pruritus, but do not have sufficient effect on lesions. Adjuvant therapy includes UV irradiation, preferably UVA1 or narrow-band UVB 311 nm. Dietary recommendations should be patient specific and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. 'Eczema school' educational programmes have been proven to be helpful for children and adults. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Global Allergy Forum and 3rd Davos Declaration 2015.
- Author
-
Bieber, T., Akdis, C., Lauener, R., Traidl‐Hoffmann, C., Schmid‐Grendelmeier, P., Schäppi, G., Allam, J.‐P., Apfelbacher, C., Augustin, M., Beck, L., Biedermann, T., Braun‐Fahrländer, C., Chew, F. T., Clavel, T., Crameri, R., Darsow, U., Deleuran, M., Dittlein, D., Duchna, H.‐W., and Eichenfeld, L.
- Subjects
- *
ALLERGIC conjunctivitis , *ALLERGENS , *DERMATITIS herpetiformis , *FOOD allergy , *IMMUNOLOGIC diseases - Abstract
The author discusses the results of the 3rd Global Allergy Forum held in Davos, Switzerland and was sponsored by the Center for Allergy Research and Education (CK-CARE). The author mentions the standardization of the epidemiology of the atopic dermatitis (AD) and its etiology and treatment. The author cites the discussion of other issues related on AD including the establishment of global registries.
- Published
- 2016
- Full Text
- View/download PDF
31. Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite.
- Author
-
Zhong, H., Deng, X., Song, Z., Darsow, U., Chen, W., Chen, S., Luo, N., and Hao, F.
- Subjects
- *
CLINICAL trials , *IMMUNOTHERAPY , *ATOPIC dermatitis treatment , *THERAPEUTIC use of cytokines , *TRANSFORMING growth factors - Abstract
Background Allergen-specific immunotherapy ( ASIT) is the main treatment for inducing long-term immunological and clinical tolerance in patients with IgE-mediated allergic diseases. Recent open-label and controlled studies on the efficacy of ASIT in patients with atopic dermatitis ( AD) have provided promising results. However, data about possible relationship between the improvement of clinical symptoms and changes of serum cytokines are limited. Methods Seventy-nine patients with moderate to severe AD sensitized to house dust mite ( HDM) were enrolled. Fifty-eight patients were treated with ASIT and 11 controls received only symptomatic treatment. The disease activity in AD patients was evaluated by using the patient-oriented eczema measure ( POEM) system. Serum interleukin ( IL)-4, IL-10, interferon ( IFN)-γ, transforming growth factor ( TGF) β1, total IgE, HDM-specific IgE (s-IgE) and HDM-specific IgG4 (s-IgG4) were measured before and after 2 years of therapy. Results The mean patient-oriented eczema measure system ( POEM) score of AD patients with ASIT significantly decreased after 2 years of treatment, compared to that in patients without ASIT. After ASIT, the serum levels of IL-10, TGF-β1, IFN-γ and s-IgG4 increased, while the level of IL-4 decreased. The change in the POEM score was negatively correlated with changes of serum concentration of TGF-β1, s-IgG4 and IFN-γ. Furthermore, s-IgG4 levels were positively correlated with changes in the IL-10 levels. No correlation between POEM score and serum IL-10 or IL-4 was observed. Conclusion Clinical symptoms and the quality of life of AD with HDM sensitization could be improved after 2 years of ASIT. Changes in serum IL-10, TGF-β1, s-IgG4 and IFN-γ might be considered as biomarkers to assist clinical evaluation of the therapeutic effects of ASIT in patients with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure - challenges and actions to be taken.
- Author
-
Ring, J., Akdis, C., Lauener, R., Schäppi, G., Traidl‐Hoffmann, C., Akdis, M., Ammann, W., Behrendt, H., Bieber, T., Biedermann, T., Bienenstock, J., Blaser, K., Braun‐Fahrländer, C., Brockow, K., Buters, J., Crameri, R., Darsow, U., Denburg, J. A., Eyerich, K., and Frei, R.
- Subjects
- *
ALLERGY prevention , *ASTHMA prevention , *ECZEMA , *THERAPEUTIC use of ultraviolet radiation , *AIR quality , *PREVENTION - Abstract
The article discusses the challenges in and actions to be taken to cure allergy caused by diseases such as asthma, eczema and anaphylaxis. It discusses the needs of public, which are not met like inadequate control of complex allergic diseases, lack of treatments and strategies to prevent it. It further discusses how environment plays vital role in the induction of allergic diseases as they have environmental factors like quality of air, nutrition, climate, and ultra violet radiations.
- Published
- 2014
- Full Text
- View/download PDF
33. Clinical relevance is associated with allergen-specific wheal size in skin prick testing.
- Author
-
Haahtela, T., Burbach, G. J., Bachert, C., Bindslev‐Jensen, C., Bonini, S., Bousquet, J., Bousquet‐Rouanet, L., Bousquet, P. J., Bresciani, M., Bruno, A., Canonica, G. W., Darsow, U., Demoly, P., Durham, S. R., Fokkens, W. J., Giavi, S., Gjomarkaj, M., Gramiccioni, C., Kowalski, M. L., and Losonczy, G.
- Subjects
- *
ASTHMA , *SKIN tests , *FOOD allergy , *PULMONOLOGY , *IMMUNOLOGY - Abstract
Background Within a large prospective study, the Global Asthma and Allergy European Network ( GA2 LEN) has collected skin prick test ( SPT) data throughout Europe to make recommendations for SPT in clinical settings. Objective To improve clinical interpretation of SPT results for inhalant allergens by providing quantitative decision points. Methods The GA2 LEN SPT study with 3068 valid data sets was used to investigate the relationship between SPT results and patient-reported clinical relevance for each of the 18 inhalant allergens as well as SPT wheal size and physician-diagnosed allergy (rhinitis, asthma, atopic dermatitis, food allergy). The effects of age, gender, and geographical area on SPT results were assessed. For each allergen, the wheal size in mm with an 80% positive predictive value (PPV) for being clinically relevant was calculated. Results Depending on the allergen, from 40% (blatella) to 87-89% (grass, mites) of the positive SPT reactions (wheal size ≥ 3 mm) were associated with patient-reported clinical symptoms when exposed to the respective allergen. The risk of allergic symptoms increased significantly with larger wheal sizes for 17 of the 18 allergens tested. Children with positive SPT reactions had a smaller risk of sensitizations being clinically relevant compared with adults. The 80% PPV varied from 3 to 10 mm depending on the allergen. Conclusion These 'reading keys' for 18 inhalant allergens can help interpret SPT results with respect to their clinical significance. A SPT form with the standard allergens including mm decision points for each allergen is offered for clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Response by B. Eberlein, I. León Suárez, U. Darsow, F. Ruëff, H. Behrendt, J. Ring.
- Author
-
Eberlein, B., León Suárez, I., Darsow, U., Ruëff, F., Behrendt, H., and Ring, J.
- Subjects
- *
LETTERS to the editor , *BASOPHILS - Abstract
A response by B. Eberlein and colleagues to a letter to the editor about their article "A new basophil activation test using CD63 and CCR3 in allergy to antibiotics," published in one of the previous issues of 2010, is presented.
- Published
- 2010
- Full Text
- View/download PDF
35. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis - a patient- and examiner-blinded, randomized, placebo-controlled, crossover trial.
- Author
-
Pfab, F., Kirchner, M.-T., Huss-Marp, J., Schuster, T., Schalock, P. C., Fuqin, J., Athanasiadis, G. I., Behrendt, H., Ring, J., Darsow, U., and Napadow, V.
- Subjects
- *
ACUPUNCTURE , *ANTIHISTAMINES , *ATOPIC dermatitis treatment , *ALLERGIES , *ALLERGENS , *PLACEBOS , *CROSSOVER trials - Abstract
Background Itch is the major symptom of atopic dermatitis ( AD). Acupuncture has been shown to exhibit a significant effect on experimental itch in AD. Our study evaluated acupuncture and antihistamine itch therapy (cetirizine) on type I hypersensitivity itch and skin reaction in AD using a patient and examiner-blinded, randomized, placebo-controlled, crossover trial. Methods Allergen-induced itch was evaluated in 20 patients with AD after several interventions in separate sessions: preventive (preceding) and abortive (concurrent) verum acupuncture ( VAp and VAa), cetirizine (10 mg, VC), corresponding placebo interventions (preventive, PAp, and abortive, PAa, placebo acupuncture; placebo cetirizine pill, PC) and a no-intervention control ( NI). Itch was induced on the forearm and temperature modulated over 20 min, using our validated model. Outcome parameters included itch intensity, wheal and flare size and the D2 attention test. Results Mean itch intensity ( SE: 0.31 each) was significantly lower following VAa (31.9) compared with all other groups ( PAa: 36.5; VC: 36.8; VAp: 37.6; PC: 39.8; PAp: 39.9; NI: 45.7; P < 0.05). There was no significant difference between VAp and VC ( P > 0.1), although both therapies were significantly superior to their respective placebo interventions ( P < 0.05). Flare size following VAp was significantly smaller ( P = 0.034) than that following PAp. D2 attention test score was significantly lower following VC compared with all other groups ( P < 0.001). Conclusions Both VA and cetirizine significantly reduced type I hypersensitivity itch in patients with AD, compared with both placebo and NI. Timing of acupuncture application was important, as VAa had the most significant effect on itch, potentially because of counter-irritation and/or distraction. Itch reduction following cetirizine coincided with reduced attention. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
36. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts.
- Author
-
Blank, S., Seismann, H., Michel, Y., McIntyre, M., Cifuentes, L., Braren, I., Grunwald, T., Darsow, U., Ring, J., Bredehorst, R., Ollert, M., and Spillner, E.
- Subjects
- *
ALLERGENS , *ANIMAL extracts , *VENOM resistance , *HONEYBEES , *HYMENOPTERA , *SEROTHERAPY , *PHYSIOLOGY , *THERAPEUTICS - Abstract
To cite this article: Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, Grunwald T, Darsow U, Ring J, Bredehorst R, Ollert M, Spillner E. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011; 66: 1322-1329. Abstract Background: Generalized systemic reactions to stinging hymenoptera venom constitute a potentially fatal condition in venom-allergic individuals. Hence, the identification and characterization of all allergens is imperative for improvement of diagnosis and design of effective immunotherapeutic approaches. Our aim was the immunochemical characterization of the carbohydrate-rich protein Api m 10, an Apis mellifera venom component and putative allergen, with focus on the relevance of glycosylation. Furthermore, the presence of Api m 10 in honeybee venom (HBV) and licensed venom immunotherapy preparations was addressed. Methods: Api m 10 was produced as soluble, aglycosylated protein in Escherichia coli and as differentially glycosylated protein providing a varying degree of fucosylation in insect cells. IgE reactivity and basophil activation of allergic patients were analyzed. For detection of Api m 10 in different venom preparations, a monoclonal human IgE antibody was generated. Results: Both, the aglycosylated and the glycosylated variant of Api m 10 devoid of cross-reactive carbohydrate determinants (CCD), exhibited IgE reactivity with approximately 50% of HBV-sensitized patients. A corresponding reactivity could be documented for the activation of basophils. Although the detection of the native protein in crude HBV suggested content comparable to other relevant allergens, three therapeutical HBV extracts lacked detectable amounts of this component. Conclusion: Api m 10 is a genuine allergen of A. mellifera venom with IgE sensitizing potential in a significant fraction of allergic patients independent of CCD reactivity. Thus, Api m 10 could become a key element for component-resolved diagnostic tests and improved immunotherapeutic approaches in hymenoptera venom allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
37. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe.
- Author
-
Stalder, J.-F., Barbarot, S., Wollenberg, A., Holm, E. A., De Raeve, L., Seidenari, S., Oranje, A., Deleuran, M., Cambazard, F., Svensson, A., Simon, D., Benfeldt, E., Reunala, T., Mazereeuv, J., Boralevi, F., Kunz, B., Misery, L., Mortz, C. G., Darsow, U., and Gelmetti, C.
- Subjects
- *
CHRONIC diseases , *ATOPIC dermatitis , *SEVERITY of illness index , *PATIENTS - Abstract
Background: Patient-oriented medicine is an emerging concept, encouraged by the World Health Organization, to greater involvement of the patient in the management of chronic diseases. The Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) index is a self-assessment score allowing the patient to comprehensively evaluate the actual course of atopic dermatitis (AD), using subjective and objective criteria derived mainly from the SCORAD, a validated AD severity clinical assessment tool. Objectives: To validate the PO-SCORAD index in a large European population of patients exhibiting all forms of AD severity by assessing its correlation with the SCORAD index. Patients/methods: Four hundred and seventy-one patients (185 adults, 286 children) consulting for AD in hospitals from 9 European countries were recruited. The investigators and the patients used the SCORAD and PO-SCORAD scales, respectively, to assess AD severity at inclusion (D0) and 28 ± 7 days later (D28). Results: Patient-Oriented SCORing Atopic Dermatitis and SCORAD scores were significantly correlated at D0 [r = 0.67 (95% CI: 0.62; 0.72), P < 0.0001]. Consistency was confirmed at D28, with a stronger linear correlation between both scales [r = 0.79 (95% CI: 0.75; 0.83), P < 0.0001]. Absolute changes from baseline in SCORAD and PO-SCORAD scores were also significantly correlated [r= 0.71 (95% CI: 0.64; 0.76), P < 0.0001]. Although no specific intervention was investigated, AD improved over the study, with a decrease of PO-SCORAD and SCORAD scores from D0 to D28 by )19.19% and )24.39%, respectively. The consistency of the correlations was similar in the adult and children groups. Conclusions: This study validated the use of PO-SCORAD to self-assess AD severity and demonstrated its good correlation with SCORAD. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
38. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema – a blinded, randomized, placebo-controlled, crossover trial.
- Author
-
Pfab, F., Huss-Marp, J., Gatti, A., Fuqin1,3, J., Athanasiadis, G. I., Irnich, D., Raap, U., Schober, W., Behrendt, H., Ring, J., and Darsow, U.
- Subjects
- *
ACUPUNCTURE , *ALTERNATIVE medicine , *ALLERGIES , *ECZEMA , *SKIN inflammation , *ITCHING - Abstract
To cite this article: Pfab F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irnich D, Raap U, Schober W, Behrendt H, Ring J, Darsow U. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema – a blinded, randomized, placebo-controlled, crossover trial. Allergy 2010; 65: 903–910. Background: Itch is a major symptom of allergic skin disease. Acupuncture has been shown to exhibit a significant effect on histamine-induced itch in healthy volunteers. We investigated the effect of acupuncture on type I hypersensitivity itch and skin reaction in a double-blind, randomized, placebo-controlled, crossover trial. Methods: An allergen stimulus (house dust mite or grass pollen skin prick) was applied to 30 patients with atopic eczema before (direct effect) and after (preventive effect) two experimental approaches or control observation: acupuncture at points Quchi and Xuehai [verum acupuncture (VA), dominant side], ‘placebo-point’ acupuncture (PA, dominant side), no acupuncture (NA). Itch intensity was recorded on a visual analogue scale. After 10 min, wheal and flare size and skin perfusion (via LASER-Doppler) were measured at the stimulus site, and the validated Eppendorf Itch Questionnaire (EIQ) was answered. Results: Mean itch intensity was significantly lower in VA (35.7 ± 6.4) compared to NA (45.9 ± 7.8) and PA (40.4 ± 5.8) regarding the direct effect; and significantly lower in VA (34.3 ± 7.1) and PA (37.8 ± 5.6) compared to NA (44.6 ± 6.2) regarding the preventive effect. In the preventive approach, mean wheal and flare size were significantly smaller in VA (0.38 ± 0.12 cm2/8.1 ± 2.0 cm2) compared to PA (0.54 ± 0.13 cm2/13.5 ± 2.8 cm2) and NA (0.73 ± 0.28 cm2/15.1 ± 4.1 cm2), and mean perfusion in VA (72.4 ± 10.7) compared to NA (84.1 ± 10.7). Mean EIQ ratings were significantly lower in VA compared to NA and PA in the treatment approach; and significantly lower in VA and PA compared to NA in the preventive approach. Conclusions: Acupuncture at the correct points showed a significant reduction in type I hypersensitivity itch in patients with atopic eczema. With time the preventive point-specific effect diminished with regard to subjective itch sensation, whereas it increased in suppressing skin-prick reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
39. Experimental inhalation of fragrance allergens in predisposed subjects: effects on skin and airways.
- Author
-
Schnuch, A., Oppel, E., Oppel, T., Römmelt, H., Kramer, M., Riu, E., Darsow, U., Przybilla, B., Nowak, D., and Jörres, R. A.
- Subjects
- *
ODORS , *ALLERGENS , *SKIN inflammation , *PROTECTIVE clothing , *ALLERGIES - Abstract
Background Exposure to fragrances is increasingly encountered in the environment. Some fragrances are known to be important skin and potential airway sensitizers. Objectives We investigated whether patients with contact allergy to isoeugenol (ISO) or hydroxyisohexyl-3-carboxaldehyde (HICC) would react to inhalation exposure at the level of the airways and skin. Methods Eleven patients sensitized to ISO and 10 patients sensitized to HICC were exposed for 60 min to 1000 μg m−3 of these compounds in an exposure chamber at rest, and to geraniol 1000 μg m−3 as a control. Patients wore protective clothing to prevent skin exposure. Assessments were performed prior to exposure, and immediately, 2, 5, 24 and 72 h afterwards. Results There were no significant changes in lung function but a tendency towards an increased bronchial hyper-responsiveness after exposure to any of the compounds. Laboratory parameters of inflammation did not indicate responses. Single patients reported respiratory symptoms unrelated to objective measures. In contrast, the observed skin symptoms corresponded to the patients’ specific sensitization. Four patients reported symptoms compatible with delayed-type hypersensitivity, and two demonstrated a flare after ISO. On re-exposure they did not respond to a lower, more realistic level of ISO. Conclusion Inhalation of high concentrations of fragrance contact allergens apparently poses a risk for some patients of developing manifest haematogenic contact dermatitis, while the changes in the respiratory tract are limited to symptoms in some subjects without objective changes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
40. Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema – a combined psychophysical and neuroimaging study.
- Author
-
Pfab, F., Valet, M., Sprenger, T., Huss-Marp, J., Athanasiadis, G. I., Baurecht, H. J., Konstantinow, A., Zimmer, C., Behrendt, H., Ring, J., Tölle, T. R., and Darsow, U.
- Subjects
- *
HISTAMINE , *ITCHING , *ECZEMA , *BRAIN imaging , *IMIDAZOLES - Abstract
Background: Itch is the major symptom of many allergic diseases; yet it is still difficult to measure objectively. The aim of this study was to use an evaluated itch stimulus model in lesional (LS) and nonlesional (NLS) atopic eczema (AE) skin and to characterize cerebral responses using functional magnetic resonance imaging (fMRI). Methods: Thermal modulation was performed on a histamine stimulus in randomized order on LS or NLS in rapid alternating order from 32°C (warm) to 25°C (cold). Subjective itch ratings were recorded. Additionally, fMRI measurements were used to analyze the cerebral processing ( n = 13). Healthy skin (HS) of age-matched volunteers served as control ( n = 9). Results: Mean VAS itch intensity was significantly ( P < 0.0001) higher during the relative cold [55.2 ± 8.3% (LS); 48.6 ± 8.2% (NLS)] compared to the relative warm blocks [36.0 ± 7.3% (LS); 33.7 ± 7.6% (NLS)]. Compared to HS, the itch response was delayed in LS and NLS. Itch intensity was perceived highest in LS, followed by NLS and HS. For NLS, fMRI revealed at the beginning of the itch provocation a cerebral deactivation pattern in itch processing structures (thalamus, prefrontal, cingulate, insular, somatosensory and motor cortex). During the course of stimulation, the cerebral deactivation was reduced with time and instead an activation of the basal ganglia occurred. In contrast LS showed an activation instead of deactivation pattern already at the beginning of the stimulation in the above mentioned structures. Conclusions: Moderate short-term temperature modulation led to a reproducible, significant enhancement of histamine-induced itch with the strongest effect in LS. The differences in itch perception and itch kinetics between healthy volunteers and NLS in patients point towards an ongoing central inhibitory activity patients with AE, especially at the beginning of the itch provocation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
41. GA2LEN skin test study III: Minimum battery of test inhalent allergens needed in epidemiological studies in patients.
- Author
-
Bousquet, P.-J., Burbach, G., Heinzerling, L. M., Edenharter, G., Bachert, C., Bindslev-Jensen, C., Bonini, S., Bousquet-Rouanet, L., Demoly, P., Bresciani, M., Bruno, A., Gjomarkaj, M., Canonica, G. W., Darsow, U., Durham, S., Fokkens, W. J., Giavi, S., Gramiccioni, C., Papadopoulos, N. G., and Haahtela, T.
- Subjects
- *
ANTIGENS , *EPIDEMIOLOGY , *PATIENTS , *PALYNOLOGY , *SKIN tests - Abstract
Background: The number of allergens to be tested in order to identify sensitized patients is important in order to have the most cost-effective approach in epidemiological studies. Objective: To define the minimal number and the type of skin prick test (SPT) allergens required to identify a patient as sensitized using results of the new Pan-European GA2LEN skin prick test study. Method: In a large Pan-European multicenter (17 centers in 14 countries) patient based study, a standardized panel of 18 allergens has been prick tested using a standardized procedure. Conditional approach allowed to determine the allergens selection. Result: Among the 3034 patients involved, 1996 (68.2%) were sensitized to at least one allergen. Overall, eight allergens (grass pollen, Dermatophagoides pteronyssinus, birch pollen, cat dander, Artemisia, olive pollen, Blatella and Alternaria) allowed to identified more than 95% of sensitized subjects. However, differences were observed between countries, two allergens being sufficient for Switzerland (grass pollen and cat dander) as opposed to nine for France (grass pollen, Dermatophagoides pteronyssinus, olive pollen, cat dander, Blatella, cypress, dog dander, alder and [Artemisia or Alternaria]). According to country, up to 13 allergens were needed to identify all sensitized subjects. Conclusion: Eight to ten allergens allowed the identification of the majority of sensitized subjects. For clinical care of individual patients, the whole battery of 18 allergens is needed to appropriately assess sensitization across Europe. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
42. GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe.
- Author
-
Burbach, G. J., Heinzerling, L. M., Edenharter, G., Bachert, C., Bindslev-Jensen, C., Bonini, S., Bousquet, J., Bousquet-Rouanet, L., Bousquet, P. J., Bresciani, M., Bruno, A., Canonica, G. W., Darsow, U., Demoly, P., Durham, S., Fokkens, W. J., Giavi, S., Gjomarkaj, M., Gramiccioni, C., and Haahtela, T.
- Subjects
- *
ALLERGIES , *SYMPTOMS , *ASTHMA , *ALLERGENS , *IMMUNOLOGIC diseases - Abstract
Background: Skin prick testing is the standard for diagnosing IgE-mediated allergies. A positive skin prick reaction, however, does not always correlate with clinical symptoms. A large database from a Global Asthma and Allergy European Network (GA2LEN) study with data on clinical relevance was used to determine the clinical relevance of sensitizations against the 18 most frequent inhalant allergens in Europe. The study population consisted of patients referred to one of the 17 allergy centres in 14 European countries ( n = 3034, median age = 33 years). The aim of the study was to assess the clinical relevance of positive skin prick test reactions against inhalant allergens considering the predominating type of symptoms in a pan-European population of patients presenting with suspected allergic disease. Methods: Clinical relevance of skin prick tests was recorded with regard to patient history and optional additional tests. A putative correlation between sensitization and allergic disease was assessed using logistic regression analysis. Results: While an overall rate of ≥60% clinically relevant sensitizations was observed in all countries, a differential distribution of clinically relevant sensitizations was demonstrated depending on type of allergen and country where the prick test was performed. Furthermore, a significant correlation between the presence of allergic disease and the number of sensitizations was demonstrated. Conclusion: This study strongly emphasizes the importance of evaluating the clinical relevance of positive skin prick tests and calls for further studies, which may, ultimately, help increase the positive predictive value of allergy testing. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
43. GA2LEN skin test study I: GA²LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe.
- Author
-
Heinzerling, L. M., Burbach, G. J., Edenharter, G., Bachert, C., Bindslev-Jensen, C., Bonini, S., Bousquet, J., Bousquet-Rouanet, L., Bousquet, P. J., Bresciani, M., Bruno, A., Burney, P., Canonica, G. W., Darsow, U., Demoly, P., Durham, S., Fokkens, W. J., Giavi, S., Gjomarkaj, M., and Gramiccioni, C.
- Subjects
- *
DIAGNOSIS , *ALLERGIES , *ALLERGENS , *FOOD allergy , *ASTHMA - Abstract
Background: Skin prick testing is the standard for diagnosing IgE-mediated allergies. However, different allergen extracts and different testing procedures have been applied by European allergy centres. Thus, it has been difficult to compare results from different centres or studies across Europe. It was, therefore, crucial to standardize and harmonize procedures in allergy diagnosis and treatment within Europe. Aims: The Global Asthma and Allergy European Network (GA²LEN), with partners and collaborating centres across Europe, was in a unique position to take on this task. The current study is the first approach to implement a standardized procedure for skin prick testing in allergies against inhalant allergens with a standardized pan-European allergen panel. Methods: The study population consisted of patients who were referred to one of the 17 participating centres in 14 European countries ( n = 3034, median age = 33 years). Skin prick testing and evaluation was performed with the same 18 allergens in a standardized procedure across all centres. Results: The study clearly shows that many allergens previously regarded as untypical for some regions in Europe have been underestimated. This could partly be related to changes in mobility of patients, vegetation or climate in Europe. Conclusion: The results of this large pan-European study demonstrate for the first time sensitization patterns for different inhalant allergens in patients across Europe. The standardized skin prick test with the standardized allergen battery should be recommended for clinical use and research. Further EU-wide monitoring of sensitization patterns is urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
44. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis.
- Author
-
Wollenberg, A., Flohr, C., Simon, D., Cork, M.J., Thyssen, J.P., Bieber, T., Bruin‐Weller, M.S., Weidinger, S., Deleuran, M., Taieb, A., Paul, C., Trzeciak, M., Werfel, T., Seneschal, J., Barbarot, S., Darsow, U., Torrelo, A., Stalder, J.‐F., Svensson, Å., and Hijnen, D.
- Subjects
- *
ATOPIC dermatitis , *SARS-CoV-2 , *TASK forces - Abstract
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.[[1]] Severely affected patients are often treated with immune-modulating systemic drugs.[[3]] On 11 March 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. If systemic treatment of AD needs to be paused, patients should be supplied with ample topical therapy and guidance on the amount needed to prevent flares until systemic therapy can be reinstated. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
45. Influence of short-term exposure to airborne Der p 1 and volatile organic compounds on skin barrier function and dermal blood flow in patients with atopic eczema and healthy individuals.
- Author
-
Huss-Marp, J., Eberlein-König, B., Breuer, K., Mair, S., Ansel, A., Darsow, U., Krämer, U., Mayer, E., Ring, J., and Behrendt, H.
- Subjects
- *
VOLATILE organic compounds , *ECZEMA , *SKIN inflammation , *ORGANIC compounds , *BLOOD circulation , *BLOOD flow , *EPIDEMIOLOGY - Abstract
Background Epidemiological studies indicate environmental pollutants to be involved in the increase in the prevalence of allergic diseases. In human exposure studies, volatile organic compounds (VOCs) have been shown to cause exacerbations of allergic asthma whereas, no data concerning atopic eczema (AE) are available. Objective We investigated the effect of airborne VOCs on the skin of patients with AE and controls in the presence or absence of house dust mite allergen, Der p 1. Methods In a double-blind crossover study, 12 adults with AE and 12 matched healthy volunteers were exposed on their forearms to Der p 1 and subsequently to a mixture of 22 VOCs (M22, 5 mg/m3) in a total body exposure chamber for 4 h. Transepidermal water loss (TEWL) and skin blood flow were measured in all subjects before, during and after exposure. Additionally, an atopy patch test (APT) with Der p 1 was applied to the skin after exposure. Results A significant increase in transepidermal water loss was observed 48 h after exposure to VOCs as compared with exposure with filtered air in all individuals (mean difference: +34%; 95% Confidence Interval: 7–69%). Prior Der p 1 exposure resulted in a significant rise of dermal blood flow after 48 h in patients with AE but not in controls. Six out of seven patients showed enhanced atopy patch test (APT) reactions to HDM allergen after previous exposure to VOCs. Conclusion Our results show that exposure to VOCs – at concentrations commonly found in indoor environments – can damage the epidermal barrier and enhance the adverse effect of Der p 1 on sensitized subjects with AE. These findings may contribute to a better understanding of the mechanisms underlying the increase in prevalence and exacerbation of AE. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
46. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors.
- Author
-
Ring, J., Barker, J., Behrendt, H., Braathen, L., Darsow, U., Dubertret, L., Giannetti, A., Hawk, J., Hönigsmann, H., Kemeny, L., Luger, T., Meurer, M., Murphy, G., Peserico, A., Ranki, A., Reunala, T., Saurat, J., Sterry, W., and van de Kerkhof, P.
- Subjects
- *
ECZEMA , *THERAPEUTICS , *CANCER patients , *SKIN care , *DERMATOLOGY - Abstract
Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regulatory function of the skin and may have the potential to enhance immunosuppressive ultraviolet (UV) effects. Current recommendations on UV protection in eczema patients treated with PCIs are inconsistent and have given rise to uncertainty and anxiety in patients. Therefore, the European Dermatology Forum (EDF) developed a position statement which reviews critically the available data with regard to the problem, especially analysing and commenting the limitations of rodent models for the human situation. There is no conclusive evidence from rodent trials to indicate that long-term application of TCIs is photococarcinogenic. There is a need for further studies to investigate the validity of mouse models as well as long-term cohort studies in patients using TCIs. Available data suggest that long-term application of TCIs is safe, that there is no evidence of increased skin cancer risk and that it is ethical to treat patients with TCIs when indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
47. Standard skin prick testing and sensitization to inhalant allergens across Europe – a survey from the GA2LEN network.
- Author
-
Heinzerling, L., Frew, A. J., Bindslev-Jensen, C., Bonini, S., Bousquet, J., Bresciani, M., Carlsen, K.-H., van Cauwenberge, P., Darsow, U., Fokkens, W. J., Haahtela, T., van Hoecke, H., Jessberger, B., Kowalski, M. L., Kopp, T., Lahoz, C. N., Carlsen, K. C. Lodrup, Papadopoulos, N. G., Ring, J., and Schmid-Grendelmeier, P.
- Subjects
- *
SKIN tests , *PROVOCATION tests (Medicine) , *ALLERGENS , *ALLERGIES , *MEDICAL research - Abstract
Skin prick testing (SPT) is the standard method for diagnosing allergic sensitization but is to some extent performed differently in clinical centres across Europe. There would be advantages in harmonizing the standard panels of allergens used in different European countries, both for clinical purposes and for research, especially with increasing mobility within Europe and current trends in botany and agriculture. As well as improving diagnostic accuracy, this would allow better comparison of research findings in European allergy centres. We have compared the different SPT procedures operating in 29 allergy centres within the Global Allergy and Asthma European Network (GA2LEN). Standard SPT is performed similarly in all centres, e.g. using commercial extracts, evaluation after 15–20 min exposure with positive results defined as a wheal >3 mm diameter. The perennial allergens included in the standard SPT panel of inhalant allergens are largely similar (e.g. cat: pricked in all centres; dog: 26 of 29 centres and Dermatophagoides pteronyssinus: 28 of 29 centres) but the choice of pollen allergens vary considerably, reflecting different exposure and sensitization rates for regional inhalant allergens. This overview may serve as reference for the practising doctor and suggests a GA2LEN Pan-European core SPT panel. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
48. Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults.
- Author
-
Weidinger, S., Klopp, N., Rümmler, L., Wagenpfeil, S., Baurecht, H . J., Gauger, A., Darsow, U., Jakob, T., Novak, N., Schäfer, T., Heinrich, J., Behrendt, H., Wichmann, H . E., Ring, J., and Illig, T.
- Subjects
- *
IMMUNE system , *PATHOGENIC microorganisms , *ASTHMA , *PHENOTYPES , *GENETIC polymorphisms , *ANTIGENS - Abstract
Influences of microbial pathogens are crucial for the maturation of the immune system. Caspase-recruitment domain containing protein 15 (CARD15) is a cytosolic receptor involved in bacterial recognition by antigen-presenting cells. CARD15 polymorphisms have been associated with Crohn's disease. Recently, associations with atopic phenotypes have been reported in children. Within a large population of German adults ( n=1875), we evaluated eight CARD15 polymorphisms for associations with atopic phenotypes. Subjects were phenotyped by standardized questionnaires and interviews as well as total and allergen-specific IgE measurements. Genotyping was performed using matrix-assisted laser desorption ionization – time of flight mass spectrometry. Haplotypes were estimated using the SAS/Genetics module. Subjects with a T allele at rs1077861 had a decreased risk of developing asthma (odds ratio OR=0.648, P=0.013), whereas the presence of an A allele at rs3135500 was significantly associated with an increased risk (OR=1.374, P=0.023). In addition, a CARD15 haplotype revealed to be protective against the development of asthma (OR=0.326, P=0.003). Subjects with an A allele at position rs5743266 or a T allele at rs2066842 had a significantly decreased risk of developing allergic rhinoconjunctivitis with ORs of 0.820 ( P=0.049) and 0.801 ( P=0.025). Polymorphism rs2066845 showed a significant association with increased total serum IgE (OR=2.155, P=0.006). Genetic variants of CARD15 that might result in inappropriate immunomodulation are not only associated with autoimmune diseases but also with atopic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
49. Skin Surface pH, Stratum Corneum Hydration, Trans-epidermal Water Loss and Skin Roughness Related to Atopic Eczema and Skin Dryness in a Population of Primary School Children: Clinical Report.
- Author
-
Eberlein-König, B., Schäfer, T., Huss-Marp, J., Darsow, U., Möhrenschlager, M., Herbert, O., Abeck, D., Krämer, U., Behrendt, H., and Ring, J.
- Subjects
- *
SKIN physiology , *SCHOOL children , *HYDROGEN-ion concentration - Abstract
Non-invasive investigations of skin morphology and function are standard tools to study the pathophysiology of several cutaneous disorders, yet they have not been used in population-based epidemiological studies. Here we examined skin surface pH, stratum corneum hydration, trans-epidermal water loss (TEWL) and skin roughness by profilometry in a study population comprising 377 primary school children (8-9 years old) as part of a multicentre survey on risk factors for allergic diseases in school children. Skin surface pH showed significant higher values (p=0.029) in the group with atopic eczema (n=45) compared with the group without atopic eczema; all other parameters did not differ significantly between children with and without atopic eczema. With increasing skin dryness there was a significant increase in pH values (p=0.004). Stratum corneum hydration showed a significant decrease with increasing dryness (p<0.001). Measurement of skin roughness also revealed a significant linear relationship with skin dryness (p=0.02). It is concluded that measurement of skin surface pH, corneometry and profilometry are useful non-invasive techniques to objectively assess skin dryness in epidemiological studies regarding atopic skin disease. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
50. Contact anaphylaxis and protein contact dermatitis in a cook handling chicory leaves.
- Author
-
Willi, R., Pfab, F., Huss-Marp, J., Buters, J. T. M., Zilker, T., Behrendt, H., Ring, J., and Darsow, U.
- Subjects
- *
CASE studies , *CHICORY , *CONTACT dermatitis , *ECZEMA , *SKIN inflammation , *ANAPHYLAXIS - Abstract
The article presents a case study of a 35-year-old Caucasian male cook with history of chronic eczema that affects his hands and distal forearms. Clinical report shows that the patient had experienced generalized pruritus and dyspnoea which could not be traced on his family background. Thus, the patient was advised to avoid chicory and prescribed an emergency medication kit to avoid contact anaphylaxis and protein contact dermatitis.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.